

⁹
Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 45668

Manuscript Type: ORIGINAL ARTICLE

Clinical Trials Study

Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients

Loo N *et al.* ABT-267/ABT-450/r + ABT-333 in HCV GT1

Nicole Loo, Eric Lawitz, Naim Alkhouri, Jennifer Wells, Carmen Landaverde, Angie Coste, Rossalynn Salcido, Michael Scott, Fred Poordad

Abstract

Match Overview

1	Internet 46 words crawled on 19-Mar-2019 www.gastroenterologyandhepatology.net	1%
2	Internet 43 words crawled on 07-Dec-2018 www.hcvguidelines.org	1%
3	Internet 28 words crawled on 13-Oct-2016 www.wjgnet.com	1%
4	Crossref 20 words Feld, Jordan J., Christophe Moreno, Roger Trinh, Edward Tam, Stefan Bourgeois, Yves Horsmans, Magdy Elkha	1%
5	Crossref 19 words "Abstracts of 52nd EASD Annual Meeting", Diabetologia, 2016	1%
6	Internet 16 words crawled on 20-Jan-2018 hepatitisresearchandnewsupdates.blogspot.se	<1%
7	Crossref 15 words Massard, J.. "Natural history and predictors of disease ... everity in chronic hepatitis C", Journal of Hepatology, 200	<1%
8	Internet 14 words crawled on 11-Mar-2019 dea.lib.unideb.hu	<1%
9	Internet 14 words crawled on 02-Apr-2019 f6publishing.blob.core.windows.net	<1%
10	Internet 13 words crawled on 24-Mar-2017 www.hepatitis.va.gov	<1%
11	Crossref 13 words Tamura, Kazuo, Yasukazu Kawai, Toru Kiguchi, Masatak a Okamoto, Masahiko Kaneko, Makoto Maemondo, Keni	<1%

[全部](#)[图片](#)[新闻](#)[购物](#)[地图](#)[更多](#)[设置](#)[工具](#)

找到约 5 条结果 (用时 0.46 秒)

ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients. Brief Summary: This is a study of combination direct-acting antiviral agents (DAA) with or without **ribavirin** (RBV) in **patients** with chronic **Hepatitis C Virus (HCV)**.

[ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and ...](#)

<https://clinicaltrials.gov/ct2/show/NCT01464827>

 [关于这条结果的详细信息](#)

 [反馈](#)

[ABT-450/ ritonavir and ABT-267 in combination with ABT-333 for the ...](#)

<https://www.ncbi.nlm.nih.gov/pubmed/25800085>  [翻译此页](#)

作者: AA Minaei - 2015 - 被引用次数: 7 - [相关文章](#)

INTRODUCTION: The global prevalence of chronic **hepatitis C virus (HCV)** is estimated to be 80 - 115 million and currently viremic infections account for 350,000 deaths annually. ... The unique combination of **ABT-450** (paritaprevir) and **ABT-267** (ombitasvir) provides highly effective treatment for **patients** with genotype 1 **HCV**.

缺少字词: HEARTLAND: Ribavirin Real World

[Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ...](#)

<https://www.ncbi.nlm.nih.gov/pubmed/27611776>  [翻译此页](#)

作者: R Flisiak - 2016 - 被引用次数: 63 - [相关文章](#)

2016年9月9日 - **Real-world** effectiveness and safety of ombitasvir/paritaprevir/**ritonavir** ± dasabuvir ± **ribavirin** in **hepatitis C**: AMBER study. ... RESULTS: A total of 209 **patients** with chronic **hepatitis C** were enrolled, most were genotype ... **ABT-267**; **ABT-333**; **ABT-450**; Anilides; Antiviral Agents; Carbamates; Macrocyclic ...

缺少字词: HEARTLAND:



All

Images

Videos

翻译成中文

关闭取词

17,600 Results

Any time ▾

Images of Ombitasvir/paritaprevir/ritonavir + dasabuvi...

bing.com/images


See more images of Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients

Real-world effectiveness of ombitasvir/paritaprevir ...

<https://onlinelibrary.wiley.com/doi/full/10.1111/jvh.12722>

Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis

Cited by: 17

Author: Heiner Wedemeyer, Antonio Craxi, Eli Zu...

Publish Year: 2017

Ombitasvir, paritaprevir, ritonavir, dasabuvir and ...

www.ncbi.nlm.nih.gov › ... › v.22(8); 2016 Feb 28

Feb 28, 2016 · Keywords: Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, Ribavirin, Hepatitis C virus cirrhosis, Hepatocellular carcinoma Core tip: Interferon-free regimens based on a combination of different direct acting antivirals (DAAs) are intensively studied in patients with hepatitis C virus (HCV)-related cirrhosis who are previous null responders or ...

Cited by: 3

Author: Zahariy Krastev, Deian Jelev, Krasimir Ant...

Publish Year: 2016

Ombitasvir/paritaprevir/ritonavir plus dasabuvir treatment ...

https://www.researchgate.net/publication/322921692_Ombitasvir...

Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis ...

Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or ...

<https://www.sciencedirect.com/science/article/pii/S2468024918302274>

T.M. Welzel, H. Hinrichsen, C. Sarrazin, et al. Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German hepatitis C registry

[全部](#)[图片](#)[新闻](#)[购物](#)[地图](#)[更多](#)[设置](#)[工具](#)

找到约 24,000 条结果 (用时 0.42 秒)

The 3-direct-acting antiviral regimen of **ombitasvir/paritaprevir/ritonavir + dasabuvir** (3D) **+/- ribavirin** (RBV) has been shown to be safe and effective for the treatment of chronic **hepatitis C** (CHC) in randomized controlled trials. However, data on **real world** treatment experience is limited. 2018年3月1日

[REAL WORLD EXPERIENCE WITH OMBITASVIR/PARITAPREVIR/R ...](#)

https://academic.oup.com/jcag/article/1/suppl_1/329/4916349

关于这条结果的详细信息 反馈

[Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir ...](#)

<https://www.ncbi.nlm.nih.gov/pubmed/28480525> - [翻译此页](#)

作者: H Wedemeyer - 2017 - 被引用次数: 23 - 相关文章

2017年7月3日 - **Real-world** effectiveness of **ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin** in **patients** with **hepatitis C** virus genotype 1 or 4 infection: A ...

[Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and ...](#)

<https://www.ncbi.nlm.nih.gov/pubmed/28370222> - [翻译此页](#)

作者: M Mendizabal - 2017 - 被引用次数: 8 - 相关文章

2017年6月6日 - **Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin** is safe and effective in **HCV**-infected **patients** in a **real-life** cohort from Latin America.

[Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ...](#)

<https://www.ncbi.nlm.nih.gov/pubmed/27611776> [翻译此页](#)

作者: R Flisiak - 2016 - 被引用次数: 68 - 相关文章

2016年9月9日 - **Real-world** effectiveness and safety of **ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin** in **hepatitis C**: AMBER study. ... METHODS: **Patients** enrolled for treatment with OBV/PTV/r ...